FLUKIVER BOVIS 50 MG/ML SOLUTION FOR INJECTION FOR CATTLE

Maa: Irlanti

Kieli: englanti

Lähde: HPRA (Health Products Regulatory Authority)

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
12-06-2017

Aktiivinen ainesosa:

CLOSANTEL SODIUM DIHYDRATE

Saatavilla:

Elanco Animal Health, Eli Lilly and Company Limited

ATC-koodi:

QP52AG09

INN (Kansainvälinen yleisnimi):

CLOSANTEL SODIUM DIHYDRATE

Annos:

50 Mg/Ml

Lääkemuoto:

Solution for Injection

Prescription tyyppi:

LM: Licensed Merchant as defined in relevant national legislation

Terapeuttinen ryhmä:

Cattle

Terapeuttinen alue:

closantel

Käyttöaiheet:

Endoparasiticide

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2012-10-12

Valmisteyhteenveto

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
FLUKIVER BOVIS 50 mg/ml Solution for Injection for cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Solution for injection.
Clear yellow to amber solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of liver fluke, gastro-intestinal
nematodes and arthropods.
TREMATODES
_Fasciola hepatica_
_Fasciola gigantica_
NEMATODES
_Haemonchus placei_
_Bunostomum phlebotomum_
_Oesophagostomum radiatum_
ARTHROPODS
_Hypoderma bovis_
_Hypoderma lineatum_
Each ml contains:
ACTIVE SUBSTANCE:
Closantel
50
mg
(equivalent to closantel sodium dihydrate
54.375 mg)
EXCIPIENTS:
Propylene glycol
414.4
mg
For the full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_3_
_1_
_/_
_0_
_7_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_0_
_1_
_2_
_4_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.3 CONTRAINDICATIONS
See section 4.11.
Do not administer to animals with known hypersensitivity to the active
ingredient.
Not for i.v. or i.m. use.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of
development of resistance and
could ultimately result in ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Underdosing,
which ma
                                
                                Lue koko asiakirja
                                
                            

Etsi tähän tuotteeseen liittyviä ilmoituksia